To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill reauthorizes the federal sickle cell disease demonstration program for another five years (2024-2028) and nearly doubles its annual funding from $4.5 million to $8.2 million. It also refines the program's focus from general 'prevention and treatment' to specifically treating sickle cell disease while preventing and treating its complications.
Who Benefits and How
Patients with sickle cell disease benefit from increased federal investment in treatment programs and research into complications of their condition. Healthcare providers and community health organizations can receive federal grants (a new option added by this bill) or contracts to operate demonstration projects. Research institutions studying heritable blood disorders gain congressional support for expanded research funding.
Who Bears the Burden and How
The federal government bears the cost of increased appropriations (approximately $3.75 million more per year). There are no new compliance burdens or costs imposed on private sector entities or individuals.
Key Provisions
- Increases annual appropriations from $4,455,000 to $8,205,000 for fiscal years 2024-2028
- Adds grant-making authority alongside existing contract and cooperative agreement mechanisms
- Refocuses program language on treating sickle cell disease and preventing/treating its complications
- Includes Sense of Congress supporting further research on heritable blood disorders including sickle cell disease
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Reauthorizes and expands funding for the sickle cell disease prevention and treatment demonstration program under the Public Health Service Act, nearly doubling annual appropriations from $4.455M to $8.205M for fiscal years 2024-2028.
Key Policy Areas
Healthcare, Public Health, Medical Research
Primary Purpose
Reauthorizes and expands funding for the sickle cell disease prevention and treatment demonstration program under the Public Health Service Act, nearly doubling annual appropriations from $4.455M to $8.205M for fiscal years 2024-2028.
Policy Domains
Sickle Cell Disease Demonstration Program Reauthorization
Identified Gains
- Sickle cell disease patients
- Healthcare providers treating sickle cell disease
- Community health organizations
- Medical research institutions
Identified Costs
- Federal government (increased appropriations)
Sponsors
Legislative Progress
ReportedReported by Mr. Sanders, without amendment
Mr. Scott of South Carolina (for himself, Mr. Booker, and …
Mr. Scott of South Carolina (for himself and Mr. Booker) …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Healthcare providers and clinics treating sickle cell disease
Community health organizations serving sickle cell patients
Medical research institutions studying heritable blood disorders
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology